Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Novartis AG — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.75, while Novartis AG trades at $153 (market cap $293.03B). The key difference: Novartis AG pays a 3.08% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | NVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $168.62 |
52-Week Low | $10.26 | $113.50 |
Market Cap | — | $293.03B |
Enterprise Value | — | $333.05B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
Novartis (NVS) trades at $154.05, down 0.37% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 75.38% gross margins and 35.21% ROE, though recent Q1 2026 earnings missed expectations. Recent developments include the $1.5B Myricx Bio acquisition expanding oncology capabilities and positive clinical trial results for neuromuscular and skin disorder treatments.
Investment outlook remains favorable with analyst consensus leaning hold (68%) amid solid fundamentals. Key opportunities include pipeline expansion through acquisitions, while risks involve execution of recent deals and competitive pressures in pharmaceuticals. The stock presents a balanced profile for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
